AMGN Amgen Inc
Price (delayed)
$328.75
Market cap
$176.61B
P/E Ratio
43.14
Dividend/share
$9.13
EPS
$7.62
Enterprise value
$224.73B
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
Highlights
The revenue has grown by 19% year-on-year and by 2.7% since the previous quarter
The debt has declined by 7% year-on-year
The P/E is 77% above the 5-year quarterly average of 24.4 and 2.2% above the last 4 quarters average of 42.2
AMGN's EPS is down by 39% year-on-year and by 3.4% since the previous quarter
Key stats
What are the main financial stats of AMGN
Market
Valuations
Earnings
Shares outstanding
537.2M
Market cap
$176.61B
Enterprise value
$224.73B
Price to earnings (P/E)
43.14
Price to book (P/B)
30.07
Price to sales (P/S)
5.28
EV/EBIT
28.95
EV/EBITDA
16.83
EV/Sales
6.72
Revenue
$33.42B
Gross profit
$20.57B
Operating income
$7.26B
Net income
$4.09B
EBIT
$7.76B
EBITDA
$13.36B
Free cash flow
$10.39B
Per share
Balance sheet
Liquidity
EPS
$7.62
EPS diluted
$7.56
Free cash flow per share
$19.36
Book value per share
$10.93
Revenue per share
$62.24
TBVPS
$84.74
Total assets
$91.84B
Total liabilities
$85.96B
Debt
$60.1B
Equity
$5.88B
Working capital
$5.93B
Debt to equity
10.23
Current ratio
1.26
Quick ratio
0.81
Net debt/EBITDA
3.6
Margins
Efficiency
Dividend
EBITDA margin
40%
Gross margin
61.5%
Net margin
12.2%
Operating margin
21.7%
Return on assets
4.5%
Return on equity
67.2%
Return on invested capital
10.5%
Return on capital employed
11.3%
Return on sales
23.2%
Dividend yield
2.78%
DPS
$9.13
Payout ratio
119.8%
AMGN stock price
How has the Amgen stock price performed over time
Intraday
1.2%
1 week
5.78%
1 month
11.52%
1 year
20.09%
YTD
26.13%
QTD
26.13%
Financial performance
How have Amgen's revenue and profit performed over time
Revenue
$33.42B
Gross profit
$20.57B
Operating income
$7.26B
Net income
$4.09B
Gross margin
61.5%
Net margin
12.2%
The net margin has declined by 49% year-on-year and by 6% since the previous quarter
The net income has contracted by 39% YoY and by 3.3% from the previous quarter
The company's operating margin fell by 23% YoY but it rose by 14% QoQ
The revenue has grown by 19% year-on-year and by 2.7% since the previous quarter
Growth
What is Amgen's growth rate over time
Valuation
What is Amgen stock price valuation
P/E
43.14
P/B
30.07
P/S
5.28
EV/EBIT
28.95
EV/EBITDA
16.83
EV/Sales
6.72
The P/E is 77% above the 5-year quarterly average of 24.4 and 2.2% above the last 4 quarters average of 42.2
AMGN's EPS is down by 39% year-on-year and by 3.4% since the previous quarter
Amgen's equity has decreased by 22% from the previous quarter and by 6% YoY
The stock's price to book (P/B) is 14% more than its last 4 quarters average of 26.4 and 3.3% more than its 5-year quarterly average of 29.1
The revenue has grown by 19% year-on-year and by 2.7% since the previous quarter
The P/S is 6% more than the last 4 quarters average of 5.0
Efficiency
How efficient is Amgen business performance
AMGN's return on sales is down by 39% year-on-year and by 4.5% since the previous quarter
AMGN's return on assets is down by 38% year-on-year
The ROE has contracted by 35% YoY
The ROIC has contracted by 28% YoY
Dividends
What is AMGN's dividend history
DPS
$9.13
Dividend yield
2.78%
Payout ratio
119.8%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Amgen financials performed over time
Amgen's total assets is 7% more than its total liabilities
Amgen's current ratio has decreased by 24% YoY and by 4.5% from the previous quarter
AMGN's quick ratio is down by 18% year-on-year
AMGN's debt to equity is up by 28% QoQ
Amgen's equity has decreased by 22% from the previous quarter and by 6% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.